PP
MRNA icon

PFS Partners’s Moderna MRNA Stock Holding History

PFS Partners’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-11
Closed -$553 – 610
2026
Q1 		$553 Sell
11
-6
-35% -$280 ﹤0.01% 566
2025
Q4 		$498 Buy
17
+6
+55% +$163 ﹤0.01% 564
2025
Q3 		$282 Hold
11
– – ﹤0.01% 547
2025
Q2 		$301 Hold
11
– – ﹤0.01% 490
2025
Q1 		$309 Hold
11
– – ﹤0.01% 425
2024
Q4 		$453 Hold
11
– – ﹤0.01% 424
2024
Q3 		$728 Sell
11
-21
-66% -$1.93K ﹤0.01% 420
2024
Q2 		$3.8K Hold
32
– – ﹤0.01% 359
2024
Q1 		$3.41K Hold
32
– – ﹤0.01% 384
2023
Q4 		$3.18K Hold
32
– – ﹤0.01% 383
2023
Q3 		$3.31K Hold
32
– – ﹤0.01% 375
2023
Q2 		$3.89K Hold
32
– – ﹤0.01% 382
2023
Q1 		$4.92K Hold
32
– – ﹤0.01% 281
2022
Q4 		$5.75K Buy
+32
New +$5.23K 0.01% 259
2022
Q1 		– Sell
-20
Closed -$5.08K – 359
2021
Q4 		$5.08K Buy
+20
New +$5.85K ﹤0.01% 259

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

PFS Partners's MRNA Position: Q2 2026 in Review

PFS Partners sold out of Moderna (MRNA) in Q2 2026, closing a stake of 11 shares — an estimated $553 sold.

PFS Partners first reported a position in MRNA in Q4 2021 and held it in 15 quarters. The position peaked at $5.75K in Q4 2022. 782 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • PFS Partners reported no remaining Moderna position as of Q2 2026 after selling out during the quarter.
  • PFS Partners sold 11 Moderna shares in Q2 2026, an estimated $553.
  • PFS Partners first reported a position in Moderna in Q4 2021 and held it in 15 quarters.
  • PFS Partners's Moderna position peaked at $5.75K in Q4 2022.
  • 782 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on PFS Partners's 13F filing for Q2 2026, filed 20 Jul 2026.